Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 4th edition, 372 pages

+ the daily Top 10

  Malignant Melanoma

  Free Subscription


1 Cancer
1 Int J Cancer
1 J Am Acad Dermatol
1 J Immunother
2 J Surg Oncol
3 Melanoma Res
1 Nat Med
1 Oncogene
2 Ophthalmol Retina
1 Ophthalmology
1 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles


    Research notes largest yearly decline in melanoma deaths.
    Cancer. 2020;126:3173.

    Int J Cancer

  2. VAN ZEIJL MCT, Ismail RK, de Wreede LC, van den Eertwegh AJM, et al
    Real-world outcomes of advanced melanoma patients not represented in phase III trials.
    Int J Cancer. 2020 Jun 19. doi: 10.1002/ijc.33162.
    PubMed         Abstract available

    J Am Acad Dermatol

  3. SHAH PV, Choi JN, Fiessinger L, Nardone B, et al
    Utilization of immunotherapy among stage 4 melanoma patients: an analysis of the National Cancer Database from 2012-2016.
    J Am Acad Dermatol. 2020 Jun 14. pii: S0190-9622(20)31092.

    J Immunother

  4. GKOUFA A, Gogas H, Diamantopoulos PT, Ziogas DC, et al
    Encephalitis in a Patient With Melanoma Treated With Immune Checkpoint Inhibitors: Case Presentation and Review of the Literature.
    J Immunother. 2020 Jun 16. doi: 10.1097/CJI.0000000000000326.
    PubMed         Abstract available

    J Surg Oncol

    Minimally invasive inguinal lymphadenectomy.
    J Surg Oncol. 2020;122:96-98.
    PubMed         Abstract available

  6. CARR MJ, Sun J, Zager JS
    Isolated limb infusion: Institutional protocol and implementation.
    J Surg Oncol. 2020;122:99-105.
    PubMed         Abstract available

    Melanoma Res

  7. TAS F, Erturk K
    Paradox in melanoma: more patients fewer publications.
    Melanoma Res. 2020 Jun 23. doi: 10.1097/CMR.0000000000000684.
    PubMed         Abstract available

  8. ZANELLA A, Doussot A, Puzenat E, Aubin F, et al
    MEK inhibitors combined with programmed cell death-1 blockade immunotherapy for metastatic uveal melanoma: is it warranted?
    Melanoma Res. 2020 Jun 23. doi: 10.1097/CMR.0000000000000677.
    PubMed         Abstract available

  9. HADFIELD MJ, Helsing R, Grant-Kels JM
    Desmoplastic melanoma: an updated clinical review and the emerging role of genetic markers and immunotherapies.
    Melanoma Res. 2020 Jun 23. doi: 10.1097/CMR.0000000000000679.
    PubMed         Abstract available

    Nat Med

  10. LIU D, Schilling B, Liu D, Sucker A, et al
    Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.
    Nat Med. 2020 Jun 19. pii: 10.1038/s41591-020-0975.
    PubMed         Abstract available


  11. ZHANG X, Yang L, Szeto P, Abali GK, et al
    The Hippo pathway oncoprotein YAP promotes melanoma cell invasion and spontaneous metastasis.
    Oncogene. 2020 Jun 19. pii: 10.1038/s41388-020-1362.
    PubMed         Abstract available

    Ophthalmol Retina

  12. LIU TYA, Zhu H, Chen H, Arevalo JF, et al
    Gene Expression Profile Prediction in Uveal Melanoma Using Deep Learning: a Pilot Study for Development of an Alternative Survival Prediction Tool.
    Ophthalmol Retina. 2020 Jun 18. pii: S2468-6530(20)30251.
    PubMed         Abstract available

  13. MURRAY TG, Latiff A, Villegas VM, Gold AS, et al
    Aflibercept for Radiation Maculopathy Study: A Prospective, Randomized Clinical Study.
    Ophthalmol Retina. 2019;3:561-566.
    PubMed         Abstract available


  14. ESPENSEN CA, Kiilgaard JF, Appelt AL, Fog LS, et al
    Dose-response and normal tissue complication probabilities after proton therapy for choroidal melanomas.
    Ophthalmology. 2020 Jun 20. pii: S0161-6420(20)30572.
    PubMed         Abstract available

    PLoS One

  15. GRZYWA TM, Klicka K, Paskal W, Dudkiewicz J, et al
    miR-410-3p is induced by vemurafenib via ER stress and contributes to resistance to BRAF inhibitor in melanoma.
    PLoS One. 2020;15:e0234707.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.